Katerina Bouchalova

Summary

Country: Czech Republic

Publications

  1. ncbi request reprint Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment
    Katerina Bouchalova
    Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 154:281-8. 2010
  2. doi request reprint High lapatinib plasma levels in breast cancer patients: risk or benefit?
    Magdalena Cizkova
    Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
    Tumori 98:162-5. 2012
  3. ncbi request reprint Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment
    Katerina Bouchalova
    Department of Paediatrics, Faculty of Medicine and Dentistry, Laboratory of Experimental Medicine, Palacky University and University Hospital, Olomouc, Czech Republic
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 153:13-7. 2009
  4. doi request reprint Collagen triple helix repeat containing 1 protein, periostin and versican in primary and metastatic breast cancer: an immunohistochemical study
    Gvantsa Kharaishvili
    Department of Clinical and Molecular Pathology, Laboratory of Molecular Pathology, Institute of Molecular and Translational Medicine, Palacky University and University Hospital, Olomouc, Czech Republic
    J Clin Pathol 64:977-82. 2011

Collaborators

  • Marian Hajduch
  • Bohuslav Melichar
  • Magdalena Cizkova
  • Gvantsa Kharaishvili
  • Michaela Zezulov√°
  • Anna Janostakova
  • Lenka Radova
  • Miloslava Zlevorov√°
  • David Friedecky
  • Radek Trojanec
  • Karel Cwiertka
  • Adriana Polynkova
  • Jan Bouchal
  • Giorgi Mgebrishvili
  • Zdenek Kolar

Detail Information

Publications4

  1. ncbi request reprint Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment
    Katerina Bouchalova
    Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 154:281-8. 2010
    ..However, only HER2 is currently used for therapy indications and new predictors for the treatment with lapatinib are sought...
  2. doi request reprint High lapatinib plasma levels in breast cancer patients: risk or benefit?
    Magdalena Cizkova
    Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
    Tumori 98:162-5. 2012
    ..The aim of the present study was to determine lapatinib plasma levels in breast cancer patients treated with lapatinib plus capecitabine...
  3. ncbi request reprint Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment
    Katerina Bouchalova
    Department of Paediatrics, Faculty of Medicine and Dentistry, Laboratory of Experimental Medicine, Palacky University and University Hospital, Olomouc, Czech Republic
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 153:13-7. 2009
    ..However, molecular targets and predictors for the treatment of triple negative breast carcinoma do not currently exist...
  4. doi request reprint Collagen triple helix repeat containing 1 protein, periostin and versican in primary and metastatic breast cancer: an immunohistochemical study
    Gvantsa Kharaishvili
    Department of Clinical and Molecular Pathology, Laboratory of Molecular Pathology, Institute of Molecular and Translational Medicine, Palacky University and University Hospital, Olomouc, Czech Republic
    J Clin Pathol 64:977-82. 2011
    ..It is an extracellular matrix protein which is also abnormally expressed in the tumour microenvironment. CTHRC1 has not been studied in breast cancer by immunohistochemistry...